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The almost constantly appearing amyloid deposits in islets
of Langerhans of individuals with type 2 diabetes was for
long time regarded as more or less innocent bystanders.
Even after that the amyloid was shown to be an aggre-
gated form of a novel polypeptide hormone, islet amyloid
polypeptide (IAPP or amylin), the deposits themselves
attracted little interest. This can appear peculiar today
and is in sharp contrast to another localized form of
amyloid deposition occurring in the brain particularly in
association with Alzheimer’s disease. The protein forming
the brain amyloid, Aβ-peptide, was discovered just two
years (1984) before IAPP (1986), and aggregation of Aβ
became immediately a central issue in the studies of the
pathogenesis of Alzheimer’s disease. So, why did almost
the whole research ﬁeld on senile and presenile dementia
so rapidly focus on amyloid while most diabetologists,
with a few exceptions, disregarded islet amyloid? A possible
reason is that while Alzheimer researchers fumbled after
a possible pathogenic mechanism for the brain pathology,
the research ﬁeld of type 2 diabetes was already established
and in a high degree directed towards the development of
insulin resistance. Many researchers regarded the obvious
failure of beta-cells only as a secondary event due to
some elusive mechanism of “glucose toxicity.” In addition,
experimentalists in diabetes research most often used mice
or rats as models, and in these species, islet amyloid cannot
develop due to the amino acid sequence of their IAPP
molecules.
After the discovery of IAPP, there was a strong interest
in the possible physiological role of the molecule and in the
eﬀect it may have on the development of type 2 diabetes. It
was found early that the peptide induces insulin insensitivity
in peripheral tissues. However, this eﬀect was reached only
afternonphysiologicallevelsofIAPP.Moreestablishedeﬀects
of the peptide include regulation of satiety, gastric emptying
and para- or autocrine signalling of insulin, and glucagon
secretion. All these eﬀects seem to modulate the action of
insulin, leading to a more even blood glucose level. Since
IAPP is a beta-cell product and these cells are lost in type
1 diabetes, IAPP in a modiﬁed form has been introduced as
supplement to insulin treatment.
Today, however, we can note an increasing interest in
the importance of the development of IAPP-derived islet
amyloid on the beta-cell function. Earlier it was believed
that islet amyloid could not be of any signiﬁcance since
even in cases with pronounced deposits, there are always
well-granulated beta-cells left. There are two essentially new
ﬁndings that are of particularly great interest. First, islet
amyloid may initially assemble intracellularly with severe
consequences for the aﬀected cell. Second, there is growing
evidence that small, oligomeric, preﬁbrillar aggregates of
IAPParedirectlytoxictobeta-cells.Interestingly,thereisalso
increasing evidence that this reﬂects a generic mechanism
common to many protein aggregates in which beta-sheet
formation are essential. Such aggregates of often completely
nonrelated peptides seem to have similar or identical eﬀects2 Experimental Diabetes Research
on cells. It is still very incompletely understood which these
eﬀects are. Eventually, the interactions may lead to cell death,
and aggregated IAPP is a strong candidate as an important
cause of beta-cell loss in type 2 diabetes. Cell death and
accumulation of diﬀuse amyloid deposits within the islet
of Langerhans are suﬃcient to destroy the islet architecture
which is important for maintaining optimal signaling.
The ﬁnding that isolated normal human islets, trans-
planted into nude mice, very rapidly develop IAPP-derived
amyloid deposits intra- and extracellularly, lead to the
suspicion that such an event could be an important cause
of the loss of function of islets transplanted into type 1
diabetic individuals. This hypothesis was recently strongly
supported by the analysis of a liver of a deceased person, who
had received intraportal islet transplants on three occasions.
Almost 50% of identiﬁed islets were found to contain
amyloid deposits. Obviously, this may mean that a beta-cell
lesion, typical of type 2 diabetes, may develop in originally
normal islets transplanted into a type 1 diabetic individual.
Methods to inhibit amyloid formation may be important
to develop in order to prolong the survival of transplanted
islets.
The present issue of Experimental Diabetes Research
deals with diﬀerent aspects of islet amyloid and IAPP. We
hope that the papers will lead to further interest in this ﬁeld
which sometimes has been neglected in diabetes research.
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